SAGE Therapeutics is a neuroscience-focused company developing medicines to treat life-threatening, rare CNS disorders. Our mission is to make life better for patients with central nervous systems diseases by discovering, developing, and delivering important new medicines to the market. To achieve that mission we leverage compelling science, a robust clinical foundation, strong partnerships, and a world-class team of founders, advisors, investors, scientists and managers. SAGEÍs lead program, SAGE-547, is in clinical development for super-refractory status epilepticus (SRSE) and is the first of many compounds the company is developing in its portfolio of potential seizure medicines. SAGEÍs robust chemistry platform has generated multiple new compounds that target the GABAA and NMDA receptors, which have demonstrated preclinical activity. SAGE Therapeutics is a private company launched in 2010 by an experienced team of R&D leaders, CNS experts and investors.